Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

[177Lu] Lu NNS309

Next Previous
Drug Profile

[177Lu] Lu NNS309

Alternative Names: 177Lu-NNS309; [177Lu] Lu-NNS309; FXX-489

Latest Information Update: 29 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adenocarcinoma; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 15 Oct 2024 Phase-I clinical trials in Adenocarcinoma (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Spain, Italy, France (Parenteral) (NCT06562192)
  • 15 Oct 2024 Phase-I clinical trials in Breast cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Spain, Italy, France (Parenteral) (NCT06562192)
  • 15 Oct 2024 Phase-I clinical trials in Colorectal cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Italy, Spain, France (Parenteral) (NCT06562192)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top